DC
GNCA

Diametric Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Diametric Capital’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-69,977
Closed -$164K – 184
2021
Q2 		$164K Buy
+69,977
New +$169K 0.12% 121

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diametric Capital's GNCA Position: Q3 2021 in Review

Diametric Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2021, closing a stake of 69,977 shares — an estimated $164K sold.

Diametric Capital first reported a position in GNCA in Q2 2021 and held it in 1 quarter. The position peaked at $164K in Q2 2021. 40 funds tracked by Wall St. Rank hold GNCA as of Q3 2021.

  • Diametric Capital reported no remaining Genocea Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Diametric Capital sold 69,977 Genocea Biosciences, Inc. shares in Q3 2021, an estimated $164K.
  • Diametric Capital first reported a position in Genocea Biosciences, Inc. in Q2 2021 and held it in 1 quarter.
  • Diametric Capital's Genocea Biosciences, Inc. position peaked at $164K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2021.

Based on Diametric Capital's 13F filing for Q3 2021, filed 15 Nov 2021.